Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPBR0D)

Drug Name

IPH-2102 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting MHC class I NK cell receptor 2DL3 (CD158b2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IPH-2101	DMDUVCZ	Multiple myeloma	2A83	Phase 2	[2]
mab 1-7F9	DMQOBH4	Multiple myeloma	2A83	Phase 2	[3]
------------------------------------------------------------------------------------

Drug(s) Targeting MHC class I NK cell receptor 2DL2 (CD158b1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IPH-2101	DMDUVCZ	Multiple myeloma	2A83	Phase 2	[2]
mab 1-7F9	DMQOBH4	Multiple myeloma	2A83	Phase 2	[3]
------------------------------------------------------------------------------------

Drug(s) Targeting MHC class I NK cell receptor 2DL1 (CD158A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IPH-2101	DMDUVCZ	Multiple myeloma	2A83	Phase 2	[2]
mab 1-7F9	DMQOBH4	Multiple myeloma	2A83	Phase 2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MHC class I NK cell receptor 2DL1 (CD158A)	TT4UXPE	KI2L1_HUMAN	Antagonist	[2]
MHC class I NK cell receptor 2DL2 (CD158b1)	TTU0P73	KI2L2_HUMAN	Antagonist	[2]
MHC class I NK cell receptor 2DL3 (CD158b2)	TTEX3SI	KI2L3_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01687387) Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR). U.S. National Institutes of Health.
2	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
3	Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.